317 related articles for article (PubMed ID: 26122981)
1. Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.
Casado JL; Mena A; Bañón S; Castro A; Quereda C; Moreno A; Pedreira J; Moreno S
HIV Med; 2016 Jan; 17(1):62-7. PubMed ID: 26122981
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis.
Casado JL; Mena A; Bañón S; Moreno A; Castro A; Perez-Elías MJ; Pedreira J; Moreno S
J Int AIDS Soc; 2014; 17(4 Suppl 3):19574. PubMed ID: 25394081
[TBL] [Abstract][Full Text] [Related]
3. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
[TBL] [Abstract][Full Text] [Related]
4. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
5. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.
Di Biagio A; Nicolini LA; Lorenzini P; Puoti M; Antinori A; Cozzi-Lepri A; Gori A; Vecchiet J; Mussini C; Andreoni M; Viscoli C; d'Arminio Monforte A; For The Icona Foundation Study Group
HIV Clin Trials; 2014; 15(4):151-60. PubMed ID: 25143024
[TBL] [Abstract][Full Text] [Related]
6. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
[TBL] [Abstract][Full Text] [Related]
7. Fibrosis Progression in Paired Liver Biopsies from HIV/HCV-Coinfected Patients without Prior Treatment of Hepatitis C.
Leite AG; Duarte MI; Mendes-Correa MC
J Int Assoc Provid AIDS Care; 2015; 14(5):463-8. PubMed ID: 26056147
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for grade 3-4 liver enzyme elevation in HIV and hepatitis C coinfected patients on combination antiretroviral therapy.
Chihrin S; Antoniou T; Raboud J; Shen S; Govan V; Fletcher D; Rachlis A; Kovacs C; Crouzat F; Tilley D; Chang B; Saskin R; Loutfy MR
AIDS Patient Care STDS; 2007 Jul; 21(7):469-78. PubMed ID: 17651028
[TBL] [Abstract][Full Text] [Related]
9. Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
Clotet B; Clumeck N; Katlama C; Nijs S; Witek J
J Antimicrob Chemother; 2010 Nov; 65(11):2450-4. PubMed ID: 20801782
[TBL] [Abstract][Full Text] [Related]
10. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
[TBL] [Abstract][Full Text] [Related]
11. Liver fibrosis progression in HIV/hepatitis C virus coinfected patients with normal aminotransferases levels.
Pace FH; Ferreira LE; Silva AE; Ferraz ML
Rev Soc Bras Med Trop; 2012; 45(4):444-7. PubMed ID: 22930041
[TBL] [Abstract][Full Text] [Related]
12. Liver toxicity in HIV-infected patients receiving novel second-generation nonnucleoside reverse transcriptase inhibitors etravirine and rilpivirine.
Casado JL
AIDS Rev; 2013; 15(3):139-45. PubMed ID: 24002197
[TBL] [Abstract][Full Text] [Related]
13. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D;
J Viral Hepat; 2011 Jul; 18(7):e307-14. PubMed ID: 21692942
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
Braun DL; Rauch A; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Metzner KJ; Böni J; Weber R; Fehr J
HIV Med; 2014 Nov; 15(10):625-30. PubMed ID: 24894776
[TBL] [Abstract][Full Text] [Related]
15. Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons.
Brunet L; Moodie EEM; Young J; Cox J; Hull M; Cooper C; Walmsley S; Martel-Laferrière V; Rachlis A; Klein MB; ; Cohen J; Conway B; Cooper C; Côté P; Cox J; Gill J; Haider S; Sadr A; Johnston L; Hull M; Montaner J; Moodie E; Pick N; Rachlis A; Rouleau D; Sandre R; Tyndall JM; Vachon ML; Sanche S; Skinner S; Wong D
Clin Infect Dis; 2016 Jan; 62(2):242-249. PubMed ID: 26400998
[TBL] [Abstract][Full Text] [Related]
16. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection.
Mehta SH; Thomas DL; Torbenson M; Brinkley S; Mirel L; Chaisson RE; Moore RD; Sulkowski MS
Hepatology; 2005 Jan; 41(1):123-31. PubMed ID: 15619237
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
[TBL] [Abstract][Full Text] [Related]
18. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.
Merchante N; López-Cortés LF; Delgado-Fernández M; Ríos-Villegas MJ; Márquez-Solero M; Merino D; Pasquau J; García-Figueras C; Martínez-Pérez MA; Omar M; Rivero A; Macías J; Mata R; Pineda JA;
AIDS Patient Care STDS; 2011 Jul; 25(7):395-402. PubMed ID: 21688986
[TBL] [Abstract][Full Text] [Related]
19. High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262).
Nguyen Truong T; Laureillard D; Lacombe K; Duong Thi H; Pham Thi Hanh P; Truong Thi Xuan L; Chu Thi N; Luong Que A; Vu Hai V; Nagot N; Tuaillon E; Dominguez S; Lemoine M
PLoS One; 2016; 11(5):e0153744. PubMed ID: 27148964
[TBL] [Abstract][Full Text] [Related]
20. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
Maida I; Martin-Carbonero L; Sotgiu G; Vispo E; Barreiro P; Gonzalez-Lahoz J; Soriano V
J Viral Hepat; 2010 Dec; 17(12):866-71. PubMed ID: 20088891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
